secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-06-02T21:30:08+00:00
Accession:  0001437749-26-019196
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals proposes public offering of common stock; terms not set
---------------------------------------------------------------------------

- Intends to offer common stock in underwritten public offering; no size or price disclosed.
- Underwriter granted 30-day option to purchase up to 15% additional shares on same terms.
- BTIG is lead bookrunner; Lucid Capital Markets joint bookrunner for the offering.
- Net proceeds to be used for working capital and general corporate purposes.
- Offering under effective shelf registration statement (File No. 333-288205) declared effective Dec 22, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926019196/0001437749-26-019196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926019196/nrxp20260602_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer